Clovis Oncology Inc (CLVS) was Reiterated by Stifel to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 45 from a previous price target of $30 . Stifel advised their investors in a research report released on Sep 21, 2016.
Many Wall Street Analysts have commented on Clovis Oncology Inc. Clovis Oncology Inc was Upgraded by Credit Suisse to ” Outperform” on Sep 21, 2016. Company shares were Reiterated by Mizuho on Aug 24, 2016 to “Neutral”, Firm has raised the Price Target to $ 23 from a previous price target of $15 .Clovis Oncology Inc was Initiated by SunTrust to “Buy” on Aug 5, 2016.
On the company’s financial health, Clovis Oncology Inc reported $-2.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Aug 8, 2016. Analyst had a consensus of $-2.11.During the same quarter in the previous year, the company posted $-2.10 EPS.
Clovis Oncology Inc opened for trading at $31.44 and hit $35.75 on the upside on Tuesday, eventually ending the session at $34.83, with a gain of 12.68% or 3.92 points. The heightened volatility saw the trading volume jump to 78,47,227 shares. Company has a market cap of $1,341 M.
In a different news, on Nov 3, 2015, Erle T Mast (Executive VP and CFO) sold 3,000 shares at $104.18 per share price. According to the SEC, on Oct 30, 2015, Lindsey Rolfe (officer ) sold 4,000 shares at $97.80 per share price. On Oct 16, 2015, Gillian C Ivers-read (officer ) sold 3,000 shares at $91.91 per share price, according to the Form-4 filing with the securities and exchange commission.
Clovis Oncology Inc. (Clovis) is a biopharmaceutical company focused on acquiring developing and commercializing anti-cancer agents in the United States Europe and additional international markets. The Company is developing three product candidates: Rociletinib Rucaparib and Lucitanib. Rociletinib an oral epidermal growth factor receptor (EGFR) is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib an oral inhibitor of poly (ADP-ribose) polymerase (PARP) is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3) vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.